Blue Jet Healthcare IPO: Company files DRHP for public issue. Details here
Premium- Blue Jet Healthcare IPO: The public issue with a face value of ₹2 per equity share is 100 per cent offer-for-sale (OFS)
Blue Jet Healthcare IPO: Specialty pharmaceutical and healthcare ingredient and intermediate company — Blue Jet Healthcare Limited has filed its Draft Red Herring Prospectus (DRHP) with the markets regulator, Securities and Exchange Board of India (SEBI), to raise funds through an initial public offering (IPO). The public issue with a face value of ₹2 per equity share is 100 per cent offer-for-sale (OFS) of up to 21,683,178 equity shares by promoter and selling shareholders, which comprises up to 18,366,311 by Akshay Bansarilal Arora, up to 3,316,867 by Shiven Akshay Arora (“Selling Shareholders").
Blue Jet Healthcare financials
The company is a net debt-free company as on June 30, 2022. Its revenue outlook is supported by annual and multiyear supply contracts that range from one to four years. 60% of its sales over the last 3 years have been backed by its order visibility. Over the course of three years, the company has catered to more than 350 customers across 35 countries some of them being Colgate Palmolive (India) Ltd, Unilever, Prinova US LLC, MMAG Co Ltd in the high-intensity sweetener space; Hovione Farmaciência, Olon S.p.A., Esperion Therapeutics Inc., and Bial– Portela & CA, S.A for pharmaceutical intermediates, API and CDMO area and GE Healthcare, Guerbet, Bracco, and Cambrex Karlskoga AB, in the contrast media area.
76.06% of Blue Jet Healthcare’s income in FY22 came from Europe, followed by India (17.14%), the United States of America (4.18%) besides other countries. Its revenue from operations increased by 36.94% to ₹683.47 crore for the Financial Year 2022 from ₹498.93 crore for the Financial Year 2021, primarily due to an increase in the revenue from the sales of contrast media intermediate and from the sales of high-intensity sweeteners, while profit after tax increased by 33.73% to ₹181.59 crore for the financial year 2022 from ₹135.79 crore for the same period last year.
As of March 31, 2022, it operates three manufacturing facilities, in Shahad, Ambernath, and Mahad in the state of Maharashtra, with an annual installed capacity of 200.60 KL, 607.30 KL, and 213.00 KL, respectively. In efforts of its capacity expansion in FY 21, it acquired a "greenfield" industrial facility on a leasehold basis in Ambernath. By 2025 its total annual production is expected to reach 1,513.6 KL.
Kotak Mahindra Capital Company Limited, ICICI Securities Limited, and J.P. Morgan India Private Limited are the books running lead managers and Link Intime India Private Limited is the registrar to the offer. The equity shares are proposed to be listed on BSE and NSE.
MINT PREMIUM See All
Incorporated in the year 1968 as Jet Chemicals by Late Shri BL Arora, Blue Jet Healthcare is promoted by its Executive Chairman; Akshay Bansarilal Arora. The company operates under the “Blue Jet" brand name and has competencies and manufacturing capabilities in contrast media intermediates and high intensity sweeteners, including saccharin and its salts as well as active pharmaceutical ingredients. Its business model focuses on collaboration, development, and manufacturing of complex chemistry categories. Over the past 5 decades, the company has developed over 100 products with over 40 products commercialised.
Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less